Comparison of platinum-based chemotherapy in patients older and younger than 70 years: An analysis of Southwest oncology group trials 9308 and 9509

Elizabeth M. Blanchard, James Moon, Paul J. Hesketh, Karen Kelly, Antoinette J. Wozniak, John Crowley, David R Gandara

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

PURPOSE: This retrospective analysis sought to investigate the safety, feasibility, and outcomes of platinum doublet therapy in patients aged 70 years or older with advanced non-small cell lung cancer compared with patients younger than 70 years who participated in two randomized phase III trials conducted by the Southwest Oncology Group. PATIENTS AND METHODS: Outcomes and toxicity data from fit patients with stage IIIB or stage IV non-small cell lung cancer treated with cisplatin/vinorelbine and carboplatin/paclitaxel were pooled from Southwest Oncology Group trials 9308 (S9308) and 9509 (S9509) and compared with respect to age. RESULTS: A total of 616 patients were available for efficacy analyses, of which 122 (20%) were aged 70 years or older. The median progression-free survival was 4 months in both age groups (p = 0.71), and response rates were similar. Overall survival was significantly higher in the younger patient cohort (median 9 months versus 7 months, p = 0.04). Individual parameters of toxicity were similar in both age groups. CONCLUSION: Although patients aged 70 years or older derived initial benefit from platinum-based therapy, survival was better in younger patients. Additional studies in this growing patient population are needed to develop treatment strategies that minimize toxicity and increase efficacy.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalJournal of Thoracic Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 2011

Keywords

  • Elderly
  • NSCLC (non-small cell lung cancer)
  • Platinum-based therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Comparison of platinum-based chemotherapy in patients older and younger than 70 years: An analysis of Southwest oncology group trials 9308 and 9509'. Together they form a unique fingerprint.

  • Cite this